October 25, 2024
TOPLINE: High-intensity exercise suppresses ghrelin levels more than moderate-intensity exercise, leading to a greater reduction in hunger. This effect may be more pronounced in women than […]
October 24, 2024
TOPLINE: Increases in prescriptions for both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors were observed in patients with type 1 […]
October 24, 2024
TOPLINE: A 48-week oral semaglutide treatment regimen for type 2 diabetes (T2D) reduces weight and improves liver steatosis, liver stiffness, and liver enzyme levels in patients […]
October 23, 2024
Eating a low-carbohydrate diet can help preserve beta-cell function in people with mild type 2 diabetes (T2D), potentially allowing some to achieve target glucose levels without […]
October 23, 2024
NEW YORK (Reuters) – Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their Medicaid health […]
October 22, 2024
Oral semaglutide (Rybelsus) lowered the risk for major adverse cardiovascular events (MACEs) by a significant 14% compared with placebo, Novo Nordisk announced. The topline results met […]
October 22, 2024
(Reuters) – The U.S. Food and Drug Administration has declined to approve Camurus’ drug for the treatment of a rare hormonal disorder due to deficiencies at […]
October 21, 2024
When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c […]
October 21, 2024
TOPLINE: In healthy young adults, a single 30-minute bout of outdoor aerobic exercise significantly reduces fasting and 1-hour glucose levels during an oral glucose tolerance test […]